

InDex Pharma Q4 2023 - Trading below cash, but for how long...?

Redeye update its view on InDex following the year-end report and with the current circumstances we see an interesting opportunity in the share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

InDex Pharma Q4 2023 - Trading below cash, but for how long ...?